Oncology News | pharmaphorum

News

Scotland first in Europe to back MSD drug for VHL tumours

Scotland has become the first country in Europe to recommend coverage of MSD’s Welireg as a treatment for some people with von Hippel-Lindau disease (VHL), a rare genetic

News

BMS swoops on Mirati with $5.8bn takeover offer

After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in

News

FDA panel sceptical on Lumakras confirmatory data

An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that

News

Lilly takes POINT in radiopharma push

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion.

News

Exscientia trims pipeline to focus on top cancer prospects

UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the

News

Takeda pulls Exkivity in US after failed confirmatory trial

Takeda has decided to withdraw its cancer drug Exkivity from the market, after a trial that was supposed to confirm its efficacy failed to deliver a positive result.

Scotland first in Europe to back MSD drug for VHL tumours

BMS swoops on Mirati with $5.8bn takeover offer

FDA panel sceptical on Lumakras confirmatory data

Lilly takes POINT in radiopharma push

Exscientia trims pipeline to focus on top cancer prospects

Takeda pulls Exkivity in US after failed confirmatory trial

EU clears AZ's SERD camizestrant, as FDA review drags on

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks